The Daily Biotech Pulse: Dicerna Slips On Data, Novavax Tightlipped On US Vaccine Approval, Adagio IPO
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 5)
HC Wainwright & Co. Maintains Buy on Kala Pharmaceuticals, Lowers Price Target to $11
HC Wainwright & Co. analyst Yi Chen maintains Kala Pharmaceuticals (NASDAQ:KALA) with a Buy and lowers the price target from $14 to $11.
JP Morgan Downgrades Kala Pharmaceuticals to Neutral
JP Morgan analyst Christopher Neyor downgrades Kala Pharmaceuticals (NASDAQ:KALA) from Overweight to Neutral.
Stocks That Hit 52-Week Lows On Thursday
During Thursday's morning session, 77 companies made new 52-week lows.
The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 4)
Kala Pharmaceuticals Q2 EPS $(0.57) Misses $(0.45) Estimate, Sales $3.10M Miss $5.33M Estimate
Kala Pharmaceuticals (NASDAQ:KALA) reported quarterly losses of $(0.57) per share which missed the analyst consensus estimate of $(0.45) by 26.67 percent. This is a 35.71 percent decrease over losses of $(0.42) per share